Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 15107-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#15107-1-AP, RRID:AB_10596931
- Product name
- Cadherin-16 antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated Cadherin-16 antibody (Cat. #15107-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IHC, WB, ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Cytoplasmic HMGB1 induces renal tubular ferroptosis after ischemia/reperfusion.
Cadherin-16 inhibits thyroid carcinoma cell proliferation and invasion.
Blocking connexin 43 and its promotion of ATP release from renal tubular epithelial cells ameliorates renal fibrosis.
Sestrin2 remedies podocyte injury via orchestrating TSP-1/TGF-β1/Smad3 axis in diabetic kidney disease.
Transient Receptor Potential Channel 6 Knockout Ameliorates Kidney Fibrosis by Inhibition of Epithelial-Mesenchymal Transition.
TMT-labeling Proteomics of Papillary Thyroid Carcinoma Reveal Invasive Biomarkers.
Pax8 controls thyroid follicular polarity through cadherin-16.
Zhao Z, Li G, Wang Y, Li Y, Xu H, Liu W, Hao W, Yao Y, Zeng R
International immunopharmacology 2023 Mar;116:109757
International immunopharmacology 2023 Mar;116:109757
Cadherin-16 inhibits thyroid carcinoma cell proliferation and invasion.
Yang X, Li Y, Liu G, Zha W, Liu Y
Oncology letters 2022 May;23(5):145
Oncology letters 2022 May;23(5):145
Blocking connexin 43 and its promotion of ATP release from renal tubular epithelial cells ameliorates renal fibrosis.
Xu H, Wang M, Li Y, Shi M, Wang Z, Cao C, Hong Y, Hu B, Zhu H, Zhao Z, Chu X, Zhu F, Deng X, Wu J, Zhao F, Guo J, Wang Y, Pei G, Zhu F, Wang X, Yang J, Yao Y, Zeng R
Cell death & disease 2022 May 31;13(5):511
Cell death & disease 2022 May 31;13(5):511
Sestrin2 remedies podocyte injury via orchestrating TSP-1/TGF-β1/Smad3 axis in diabetic kidney disease.
Song S, Shi C, Bian Y, Yang Z, Mu L, Wu H, Duan H, Shi Y
Cell death & disease 2022 Jul 30;13(7):663
Cell death & disease 2022 Jul 30;13(7):663
Transient Receptor Potential Channel 6 Knockout Ameliorates Kidney Fibrosis by Inhibition of Epithelial-Mesenchymal Transition.
Zhang Y, Yin N, Sun A, Wu Q, Hu W, Hou X, Zeng X, Zhu M, Liao Y
Frontiers in cell and developmental biology 2020;8:602703
Frontiers in cell and developmental biology 2020;8:602703
TMT-labeling Proteomics of Papillary Thyroid Carcinoma Reveal Invasive Biomarkers.
Dai J, Yu X, Han Y, Chai L, Liao Y, Zhong P, Xie R, Sun X, Huang Q, Wang J, Yin Z, Zhang Y, Lv Z, Jia C
Journal of Cancer 2020;11(20):6122-6132
Journal of Cancer 2020;11(20):6122-6132
Pax8 controls thyroid follicular polarity through cadherin-16.
Koumarianou P, Goméz-López G, Santisteban P
Journal of cell science 2017 Jan 1;130(1):219-231
Journal of cell science 2017 Jan 1;130(1):219-231
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- human kidney tissue were subjected to SDS PAGE followed by western blot with 15107-1-AP(CDH16 antibody) at dilution of 1:400
- Sample type
- tissue
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemical of paraffin-embedded human kidney using 15107-1-AP(CDH16 antibody) at dilution of 1:100 (under 10x lens)
- Sample type
- tissue
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The Cadherin-16 antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human Cadherin-16. This antibody recognizes human,mouse,rat antigen. The Cadherin-16 antibody has been validated for the following applications: ELISA, WB, IHC analysis.
